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Structure-based tailoring of compound libraries for
high-throughput screening: discovery of novel EphB4 kinase
inhibitors
Abstract
High-throughput docking is a computational tool frequently used to discover small-molecule inhibitors
of enzymes or receptors of known three-dimensional structure. Because of the large number of
molecules in chemical libraries, automatic procedures to prune multimillion compound collections are
useful for high-throughput docking and necessary for in vitro screening. Here, we propose an
anchor-based library tailoring approach (termed ALTA) to focus a chemical library by docking and
prioritizing molecular fragments according to their binding energy which includes continuum
electrostatics solvation. In principle, ALTA does not require prior knowledge of known inhibitors, but
receptor-based pharmacophore information (hydrogen bonds with the hinge region) is additionally used
here to identify molecules with optimal anchor fragments for the ATP-binding site of the EphB4
receptor tyrosine kinase. The 21,418 molecules of the focused library (from an initial collection of about
730,000) are docked into EphB4 and ranked by force-field-based energy including electrostatic
solvation. Among the 43 compounds tested in vitro, eight molecules originating from two different
anchors show low-micromolar activity in a fluorescence-based enzymatic assay. Four of them are active
in a cell-based assay and are potential anti-angiogenic compounds.
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Abstract
High-throughput docking is a computational tool frequently used to discover small-
molecule inhibitors of enzymes or receptors of known three-dimensional structure. Be-
cause of the large number of molecules in chemical libraries, automatic procedures to
prune multi-million compound collections are useful for high-throughput docking and
necessary for in vitro screening. Here, we propose an anchor-based library tailoring ap-
proach (termed ALTA) to focus a chemical library by docking and prioritizing molecu-
lar fragments according to their binding energy which includes continuum electrostatics
solvation. In principle, ALTA does not require prior knowledge of known inhibitors,
but receptor-based pharmacophore information (hydrogen bonds with the hinge region)
is additionally used here to identify molecules with optimal anchor fragments for the
ATP-binding site of the EphB4 receptor tyrosine kinase. The 21418 molecules of the
focused library (from an initial collection of about 730000) are docked into EphB4 and
ranked by force-field-based energy including electrostatic solvation. Among the 43 com-
pounds tested in vitro, eight molecules originating from two different anchors show low-
micromolar activity in a fluorescence-based enzymatic assay. Four of them are active in
a cell-based assay and are potential anti-angiogenic compounds.
INTRODUCTION
Docking is a successful method in computer-aided drug design.1–5 However, there is a
large and increasing discrepancy between the number of small molecules available in
computer-readable format (on the order of 107-108 compounds,6 not counting those gen-
erated by de novo design programs) and the amount of molecules that can be efficiently
processed by high-throughput approaches in silico or in vitro (on the order of 105-106).
Moreover, it is highly inefficient to use computational resources or robotic systems and
chemical reagents for compounds that have a low chance of binding to the target protein.
The essential question is how to utilize (structural) information of the target to pre-select
the molecules that are most likely to show binding and inhibitory activity. One efficient
approach exploits the available experimental knowledge of known inhibitors by using
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pharmacophore constraints to preselect compounds for docking, thereby reducing com-
putation times. In this way, inhibitors of aldose reductase7 and the MDM2 oncoprotein8
were identified.
Here, we introduce an efficient computational method to focus a library (termed
ALTA for anchor-based library tailoring) and present an application which has resulted
in the discovery of inhibitors of the erythropoietin producing human hepatocellular car-
cinoma receptor tyrosine kinase B4 (EphB4). The basic strategy of the ALTA approach
(Figure 1) has been inspired by in silico fragment-based approaches9, 10 and in vitro “nee-
dle screening” procedures.11 Needle- or anchor-based in vitro screening has been applied
to a wide range of enzymes including thrombin,11 DNA gyrase,12 and protein tyrosine
kinases.13, 14 Therefore, although only one kinase is used in this study to validate the
approach, the applicability of ALTA extends to any target enzyme for which the three-
dimensional structure and substrate binding site are known.
The receptor tyrosine kinase EphB4 is a highly attractive angiogenic target involved
in many types of cancer.15 It seems to be rather recalcitrant to inhibition because, despite
its potential therapeutic importance, only two series of nonpeptidic small molecule in-
hibitors have been reported in the literature up to date.16 The present work reports on the
efficient docking of a focused compound library, tailored by ALTA to the ATP-binding
site of EphB4. The docking of the focused library results in the identification of several
small molecules that are promising anti-angiogenic lead compounds against EphB4.
METHODS
Computational Methods. The procedure for ALTA starts from a large pool of com-
pounds and consists of six steps which are illustrated in Figure 1 together with the statis-
tics of the application to EphB4. It is important to underline that although a suite of in-
house developed softwares was used in the present study, the basic workflow can be re-
produced with any combination of softwares that is capable of carrying out all the steps.
Three libraries were combined for a total of 728202 compounds: the NCI database,17 the
ChemDiv library (Moscow, Russia) and the synthetic and natural compound library of
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InterBioScreen (Moscow, Russia). In step 1 of ALTA, the compounds were decomposed
into predominantly rigid fragments by automatic identification and cutting of rotatable
bonds.18 The three fragments with the highest chemical richness (sum over the entries
in the molecular fingerprint; cf. Fig. 2 in Ref. 18) were selected for every compound.
From the resulting set of 35513 unique fragments, candidate anchors were chosen which
fulfil the constraints imposed by the binding site (step 2 in Fig. 1). Although it is not
a requirement of ALTA to take pharmacophore constraints into account, doing so will
help to discard at an early stage fragments which are unlikely to bind. In this study, the
ability of a fragment to form the characteristic bidentate hydrogen bonds of ATP with
the hinge region of a kinase19 was used. Fragments that contained at least one ring,
one hydrogen bond donor (nitrogen, oxygen or sulfur connected to a hydrogen) and
one acceptor (nitrogen with a lone pair or oxygen) were docked with a rigid-fragment
docking program10, 20 (step 3 in Fig. 1). The presence of a ring was required to select
only fragments with a certain rigidity and thus fixed relative orientation of the donor and
acceptor group(s). Docked fragments were considered to form the bidentate hydrogen
bonds if a matching donor and acceptor were found within a radius of 3 A˚ around the
carbonyl oxygen of Glu694 and the amide nitrogen of Met696, respectively. Glu694
and Met696 are the first and last residue in the hinge region of EphB4. These fragments
were ranked according to their binding energy (step 4 in Fig. 1), which is the sum of van
der Waals interaction, electrostatic desolvation of both the receptor and the fragment and
the screened electrostatic interaction.10 There are no terms reflecting the internal energy,
since fragments are treated as rigid. Using the 1205 top-ranking fragments as queries,
21418 compounds were retrieved from the composite library of 728202 molecules (step
5 in Fig. 1). This search used an algorithm for the identification of a graph-subgraph
isomorphism21 which was implemented in DAIM,18 adapting the VFLib Graph Match-
ing Library, version 2.0 in ref. 22. Finally, in step 6, a suite of programs was used for
fragment-based10, 18 flexible-ligand docking by genetic algorithm optimization.23 The
protein was kept rigid during docking, but two structures with different orientations of
the hydroxyl group of Thr693 were used for both fragment and compound docking in
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order to allow for a greater variety of eventual hydrogen bond interactions with potential
ligands. The third column in the table of Figure 1 lists the numbers of unique fragments
(or compounds) while the fourth column lists the fragments selected for (or compounds
docked into) both structures.
EphB4 model. Since the crystal structure of the kinase domain of EphB4 is not known,
a homology model was built using the structure of EphB2 (mouse, PDB entry 1JPA24)
as template. The overall amino acid sequence identity between the human EphB4 se-
quence obtained from SWISS-PROT (accession code P54760) and the sequence derived
from the mouse EphB2 structure is 88.4 % and there are no gaps or insertions in the
aligned region. An additionally generated binary sequence alignment with the sequence
derived from the human Eph kinase structure EphA2 (PDB entry 1MQB) revealed a
lower sequence identity of 63.1 % and also three short regions containing gaps or in-
sertions. Therefore, only the sequence alignment between EphB4 (human) and EphB2
(mouse) was used in the initial phase of the homology modelling procedure. All se-
quence alignments were performed using the program ClustalW.25 The 1JPA crystal
structure comprises two chemically identical subunits in the crystallographic asymmet-
ric unit. A structural superposition of the two subunits results in an average root-mean
square deviation of 0.32 A˚ for 269 Cα atoms. Since subunit A of the 1JPA crystal struc-
ture has better main-chain dihedral angles (φ and ψ) and lower B factors, this subunit
was initially chosen as the template structure. However, the two subunits of the 1JPA
structure show some clear structural differences around the active site region. The dif-
fering amino acid residues were analyzed with respect to B factors, possible contacts
and stereochemical criteria. Subsequently, the side-chain rotamer conformations of the
initial template structure (subunit A) were replaced by the corresponding side-chain con-
formations of subunit B of the 1JPA crystal structure, if the latter were better defined ac-
cording to the above-mentioned criteria. The resulting modified structure was then used
as template for homology modelling and a total of 100 different models were generated
using the program Modeller.26, 27
The obtained initial models were ranked and analyzed based on internal energy and
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stereochemical quality. The best model was manually modified by comparison with
the active sites of the two known Eph kinase structures (PDB entry codes 1JPA and
1MQB) and other related kinase structures (PDB entry codes 1BYG, 1FMK, 1FPU,
1IEP, 1M14, 1M17, 1M52, 1MP8, 1OPK, 1OPL and 2SRC) found by PSI-BLAST28
and DALI29 searches of protein structure databases. The conformational information
contained in these homologous structures was used for manually adjusting side-chain
conformations of conserved or similar amino acid residues. If feasible on the basis of
energetic and packing criteria, side-chain χ-angles of the respective amino acid residues
were completely or partially conserved. Else, statistically preferred χ-angles were cho-
sen and favorable hydrophobic or polar contacts were taken into consideration. After
each manual change, the side-chain in question was minimized with CHARMM30 and
the CHARMm2231 force field. Moreover, an ATP molecule was modelled into the ac-
tive site to avoid structural changes during minimization. Hydrogen atoms (considering
appropriate ionization states for acidic and basic amino acid residues), CHARMm2231
atom types and partial charges were assigned to the protein and ATP using the pro-
gram WITNOTP and the MPEOE method.32, 33 This rebuilding and refinement with
CHARMM30 using the CHARMm2231 force field led to a model exhibiting excellent
stereochemical quality, with 92.9 % of the φ/ψ values in the most favored regions and
6.3 % in additionally allowed regions of the Ramachandran plot as evaluated with the
program PROCHECK.34 Finally, the ATP molecule was removed.
Minimization and ranking. After docking, multiple poses of each compound were
minimized with CHARMM30 and the CHARMm22 force field.31 Minimized poses were
filtered according to thresholds in van der Waals energy and van der Waals efficiency
(the ratio of the van der Waals energy and the molecular weight) (Suppl. Mat.). A gen-
eral linear interaction energy with continuum electrostatics (LIECE35) model was used
for the final ranking (see next paragraph).
LIECE model for kinases. The two-parameter LIECE model ∆G = α∆EvdW +
β∆Gelec was developed using a composite set of 165 known inhibitors, i.e., 73, 51,
Kolb et al., ALTA: Anchor-based library tailoring 7
and 41 inhibitors of cyclin-dependent kinase 2 (CDK2), lymphocyte-specific kinase
(Lck), and p38 mitogen-activated protein kinase (p38), respectively. It showed a very
low root-mean-square of the error (rmse) of only 1.03 kcal·mol−1 for the 165 inhibitors
used as training set in the fitting and a leave-one-out cross-validated q2 of 0.74 .36 The
values of α and β for this kinase LIECE model are 0.2898 ± 0.0075 (model with all
165 inhibitors ± standard deviation over 165 LIECE models obtained by leave-one-out)
and 0.0442 ± 0.0074, respectively. The values of these parameters are similar to those
obtained for the three models derived by fitting to each of the three kinases individu-
ally. The two-parameter three-protein LIECE model was also cross-validated on a set of
compounds not used for fitting, namely 128 known inhibitors of the epidermal growth
factor receptor (EGFR) tyrosine kinase.37 On this set, the model yielded an rmse of
1.46 kcal·mol−1. This transferability of parameters is in contrast to our previous study,35
where parameters were not transferable between HIV-1 protease (α = 0.1690 and β =
0.0168 using 24 peptidic inhibitors) and β-secretase (α = 0.2737 and β = 0.1795 us-
ing 13 peptidic inhibitors). The non-transferability between retroviral and mammalian
aspartic proteases is due to the fact that they differ not only in overall shape (HIV-1 pro-
tease is a homodimer of 99 × 2 residues while human β-secretase is a monomer of 501
residues) but also, and more importantly for LIECE, in the substrate-binding site. This
difference stems from the different polypeptide sequences of their substrates. In contrast,
the ATP-binding site of kinases, which was targeted in this study, is highly conserved in
structure.19
Kinetic assay. Compound 2 was tested in the Omnia Tyr Recombinant Kit KNZ4051
(Biosource, USA) at different concentrations between 50 nM and 100µM in a Corning
96-well microtiter plate. Fluorescence progress curves were measured upon excitation at
360 nm and emission at 485 nm. The assay contained a final concentration of EphB4 and
ATP of 25 ng/µl and 125µM (which is near itsKm), respectively, and was run at 30°C for
1 hour. To provide evidence for specific binding, a second assay was performed in which
0.01% of Triton X-100 was added to the reaction mixture (Fig. 2). Moreover, to show
the competitive behaviour of compound 2 towards ATP, different ATP concentrations
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(ranging from 31.25 to 500µM) were used (Fig. 3). IC50 values (inhibitor concentration
at which enzyme activity is reduced by 50%) and fitted curves were determined with
GraphPad Prism 5.0 (GraphPad Software).
Phospho-EphB4 ELISA of CHO cells. The ELISA assay was performed essentially as
described in Ref. 38. Briefly, Chinese hamster ovary (CHO)-FRT cells were stably trans-
fected with myc-tagged full-length human EphB4 according to the Flip-In System proto-
col (Invitrogen, USA). A clone that expressed myc-tagged human EphB4 and showed in-
ducible autophosphorylation of EphB4 upon stimulation with mouse ephrinB2-Fc (mouse
ephrinB2 fused to the Fc region of human IgG) was selected. Cells of this clone were
preincubated with EphB4 inhibitors for 15 minutes and then stimulated with preclus-
tered ephrinB2-Fc for 45 minutes at 37°C. Cells were lysed, transferred to a 96-well
plate coated with anti-myc antibody and incubated overnight at 4°C. After incubation
with anti-phosphotyrosine antibody, reactions were developed with BM Blue peroxidase
substrate and autophosphorylation of EphB4 was quantified by measuring absorption at
450 nm.
RESULTS and DISCUSSION
Library tailoring by ALTA using the EphB4 structure
Only fragments involved in two or more hydrogen bonds with the EphB4 hinge region
were considered in ALTA. Fragments were ranked according to binding energy calcu-
lated by SEED (which includes continuum electrostatics solvation). The union of the
two sets of 1000 fragments (one set for each protein structure differing in the orientation
of the hydroxyl group of Thr693, see Methods section) with the most favorable calcu-
lated binding energy consists of 1205 unique fragments. A subset of 21418 compounds
was retrieved from the composite library of 728202 molecules (step 5 in Fig. 1) using
these 1205 fragments.
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In vitro validation
Forty compounds from the high-throughput docking of the focused library of 21418
molecules were selected upon ranking (step 6 in Fig. 1) and tested first in a fluorescence-
resonance energy transfer (FRET)-based enzymatic assay (see Suppl. Mat). Ten of these
could not be measured, because they interfered with the fluorescence read-out. A com-
pound with a phenylurea anchor (1 in Table I) showed an IC50 of 76µM in the FRET-
based enzymatic assay. In the same assay, another compound with a three-ring system as
anchor (2 in Table I) showed an IC50 of about 1.6µM, with a molecular weight of only
353 Da. Five more compounds with different anchors inhibited the activity of EphB4 by
15-40 % at a concentration of 125µM (data not shown).
The ligand efficiency (LE = −∆Gexpbinding/HAC, where HAC is the number of heavy
atoms) is a useful measure for lead selection.39 Notably, inhibitor 2 has an LE value
of 0.3 kcal·mol−1 per heavy atom suggesting that it is an interesting compound for fur-
ther development. To evaluate its cell permeability and cellular activity, compound 2
was tested in CHO cells for inhibition of EphB4 autophosphorylation in a mammalian
cell-based environment. It showed only mild inhibitory effects in CHO cells at a con-
centration of 20µM. To further investigate cellular activity and determine whether lack
thereof is a general problem of this class of molecules, 13 molecules containing the
scaffold of compound 2 were purchased. (Of these, only compound 3 was present in the
original library. It had been ranked among the first 300 molecules but was not purchased
in the first round because it was considered too similar to compound 2.) Two of the 13
compounds (3 and 4) showed low-micromolar inhibitory activity in the enzymatic as-
say. Four more compounds displayed activity in the mid-micromolar range, with similar
activities when tested in CHO cells (5-8). The similar potency of inhibitors 2-8 is con-
sistent with the binding mode obtained by docking (Fig. 4) in which the flexible tail is
not involved in direct interactions with atoms in the ATP-binding site.
The compounds showing the strongest inhibition effects in the enzymatic assay (2
and 3 in Table I) were verified in a FRET-based enzymatic assay40 offered by Cerep
(France; see Suppl. Mat). Similar values of IC50 compared to the original FRET-based
Kolb et al., ALTA: Anchor-based library tailoring 10
enzymatic assay were obtained (Table I).
As a representative of the entire series, inhibitor 2 was investigated further to provide
evidence against unspecific binding due to compound aggregation. The Omnia kinetic
assay (see Methods section) was performed under two conditions, with and without the
addition of detergent (0.01% of Triton X-100). The IC50 values of inhibitor 2 in the two
experiments are 5.6 and 7.9µM, which corresponds to a Ki of 2.7 and 2.9µM, respec-
tively (Fig. 2). Such detergent-insensitive inhibition is indicative of specific binding.41
To further analyze the competitive behaviour of inhibitor 2, different ATP concen-
trations were used in the Omnia kinetic assay (ranging from 31.25 to 500µM). The data
obtained in these experiments is shown in a specific velocity plot42 (Fig. 3), where the
ratio of the initial velocities for the non-inhibited and inhibited reactions at a given ATP
concentration (v0/vi in Fig. 3) is plotted versus σ/(1+σ), with σ = [ATP]/Km. For an ATP-
competitive inhibitor, all curves should intersect close to the point (1,1), which is the
case for inhibitor 2. This result provides strong evidence that inhibitor 2 does indeed
bind to the ATP binding site, as predicted by the docking calculations (Fig. 4).
Interestingly, for both compounds 1 and 2, most of the predicted poses of the an-
chor fragment and the whole molecule showed significant overlap. In general, small
fragments docked in multiple orientations. These docking results are consistent with
a recent X-ray study of the binding modes of a 1µM inhibitor of β-lactamase and its
constitutive fragments.43
Computational requirements
It is interesting to compare the CPU time required for the preparation and docking of
the focused library with docking of all compounds in the three libraries. The ALTA
approach required about 6500 hours (on a Linux cluster with CPUs with clock speeds
of 1.7 GHz): 2 hours for decomposition into fragments, 2200 hours for fragment dock-
ing, 1000 hours for substructure search, and 3300 hours for flexible-ligand docking and
CHARMM minimization.30 The focused library contains 1/34th of the initial collection
of compounds and only about 1/3rd of the fragments, which yields a net speed-up by
a factor of about 20, a number that would be even larger in the case of flexible-protein
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docking. While the actual computation times per compound will naturally vary for other
docking programs, the speed-up achieved by library pre-processing with the ALTA pro-
cedure will remain significant.
CONCLUSIONS
The number of available small molecules is growing steadily and is already too large for
docking with accurate binding energy evaluation and prohibitive for in vitro screening. In
this paper, an automatic fragment-based procedure for focusing libraries of compounds
(termed ALTA) was presented and validated. First, molecular fragments are docked and
prioritized (i.e., anchors are selected based on a ranking) according to force field energy
which includes continuum electrostatics solvation. Large collections of molecules can
then be effectively reduced in size by selecting only the compounds for which one of the
constitutive fragments is similar to one of the top ranking anchors.
In principle, ALTA does not require any information about known ligands but in
the application presented here pharmacophore knowledge (hydrogen bonds to the hinge
region of the receptor tyrosine kinase EphB4) was additionally used to efficiently re-
duce the size of the original library from about 730000 to 21418 molecules. Two series
of novel EphB4 inhibitors have been identified in this study. The overall hit rate is very
high because only 43 compounds were tested in vitro: first 30 molecules suggested by the
ALTA approach, and in a second phase 13 compounds with the same anchor (a three-ring
system) as the most potent of the seven micromolar inhibitors among the 30 molecules.
Compound 2 is a potential candidate for further development for three reasons. First,
its low-micromolar affinity and molecular weight of only 353 Da result in a favorable
ligand efficiency (binding free energy per heavy atom). Second, the kinetic character-
ization of compound 2 indicates that it binds to the ATP-binding site, as predicted by
the docking calculations. This finding is useful for structure-based lead improvement,
e.g., by chemical synthesis of derivatives. Finally, derivatives 5-8 have shown inhibitory
activity in cell-based assays.
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The successful application of the ALTA approach suggests that the identification,
based on the structure of the active site, of anchor fragments and their use for library
filtering is an efficient strategy for inhibitor discovery by screening in silico. Besides
its usefulness for high-throughput docking, other possible applications of ALTA include
the design of combinatorial libraries and the focusing of large collections of molecules
for high-throughput or NMR-based screening in vitro.
Acknowledgements. We thank S. Jelakovic for preparing the model of EphB4, S.
Aude´tat, J. Tietz, P. Schenker and A. Baici for help with the in vitro assays and C. Bol-
liger, Th. Steenbock and A. Godknecht for help with the Matterhorn computer cluster.
We thank A. Widmer (Novartis Pharma, Basel) for providing the molecular modeling
program Wit!P which was used for visual analysis. This work was supported by grants
of the Swiss Commission for Technology and Innovation (KTI/CTI).
Software availability: Scripts for ALTA as well as the programs for molecule decom-
position into fragments (DAIM), fragment docking (SEED) and flexible-ligand docking
(FFLD) are available for free for not-for-profit institutions.
Supporting data available: Procedure for compound ranking and details of the kits
used for FRET-based and kinetic assays.
Kolb et al., ALTA: Anchor-based library tailoring 13
References
[1] Vangrevelinghe E, Zimmermann K, Schoepfer J, Portmann R, Fabbro D, Furet P.
Discovery of a potent and selective protein kinase ck2 inhibitor by high-throughput
docking. J Med Chem 2003; 46:2656–2662.
[2] Jorgensen WL. The many roles of computation in drug discovery. Science 2004;
303:1813–1818.
[3] Ding K, Lu Y, Nikolovska-Coleska Z, Qiu S, Ding Y, Gao W, Stuckey J, Krajewski
K, Roller PP, Tomita Y, et al. Structure-based design of potent non-peptide MDM2
inhibitors. J Am Chem Soc 2005; 127:10130–10131.
[4] Cozza G, Bonvini P, Zorzi E, Poletto G, Pagano MA, Sarno S, Donella-Deana A,
Zagotto G, Rosolen A, Pinna LA, et al. Identification of ellagic acid as potent
inhibitor of protein kinase CK2: A successful example of a virtual screening appli-
cation. J Med Chem 2006; 49:2363–2366.
[5] Huang D, Lu¨thi U, Kolb P, Cecchini M, Barberis A, Caflisch A. In silico discovery
of β-secretase inhibitors. J Am Chem Soc 2006; 128:5436–5443.
[6] Irwin JJ, Shoichet BK. ZINC – a free database of commercially available com-
pounds for virtual screening. J Chem Inf Model 2005; 45:177–182.
[7] Kraemer O, Hazemann I, Podjarny AD, Klebe G. Virtual screening for inhibitors of
human aldose reductase. Proteins: Structure, Function, and Bioinformatics 2004;
55:814–823.
[8] Lu Y, Nikolovska-Coleska Z, Fang X, Gao W, Shangary S, Qiu S, Qin D, Wang
S. Discovery of a nanomolar inhibitor of the human murine double minute 2
(MDM2)-p53 interaction through an integrated, virtual database screening strat-
egy. J Med Chem 2006; 49:3759–3762.
Kolb et al., ALTA: Anchor-based library tailoring 14
[9] Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy
simultaneous search method. Proteins: Structure, Function and Genetics 1991;
11:29–34.
[10] Majeux N, Scarsi M, Apostolakis J, Ehrhardt C, Caflisch A. Exhaustive docking
of molecular fragments with electrostatic solvation. Proteins: Structure, Function
and Genetics 1999; 37:88–105.
[11] Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadvary P, Labler L,
Mu¨ller K, Schmid G, Tschopp T, et al. Design and synthesis of potent and highly
selective thrombin inhibitors. J Med Chem 1994; 37:3889–3901.
[12] Bo¨hm HJ, Bo¨hringer M, Bur D, Gmu¨nder H, Huber W, Klaus W, Kostrewa D,
Ku¨hne H, Lu¨bbers T, Meunier-Keller N, et al. Novel inhibitors of DNA gyrase:
3D structure based biased needle screening, hit validation by biophysical methods,
and 3D guided optimization. a promising alternative to random screening. J Med
Chem 2000; 43:2664–2674.
[13] Traxler P, Furet P. Strategies toward the design of novel and selective protein tyro-
sine kinase inhibitors. Pharmacol Ther 1999; 82:195–206.
[14] Furet P, Bold G, Hofmann F, Manley P, Meyer T, Altmann KH. Identification of
a new chemical class of potent angiogenesis inhibitors based on conformational
considerations and database searching. Bioorg Med Chem Lett 2003; 13:2967–
2971.
[15] Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis.
Cytokine Growth Factor Rev 2002; 13:75–85.
[16] Miyazaki Y, Nakano M, Sato H, Truesdale AT, Stuart JD, Nartey EN, Hightower
KE, Kane-Carson L. Design and effective synthesis of novel templates, 3,7-
diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and
in vitro evaluation targeting angiogenetic kinases. Bioorg Med Chem Lett 2007;
17:250–254.
Kolb et al., ALTA: Anchor-based library tailoring 15
[17] Milne GWA, Nicklaus MC, Driscoll JS, Wang S, Zaharevitz DW. The NCI drug
information system 3D database. J Chem Inf Comput Sci 1994; 34:1219–1224.
[18] Kolb P, Caflisch A. Automatic and efficient decomposition of two-dimensional
structures of small molecules for fragment-based high-throughput docking. J Med
Chem 2006; 49:7384–7392.
[19] Liao JL. Molecular recognition of protein kinase binding pockets for design of
potent and selective kinase inhibitors. J Med Chem 2007; 50:409–424.
[20] Majeux N, Scarsi M, Caflisch A. Efficient electrostatic solvation model for protein-
docking. Proteins: Structure, Function and Genetics 2001; 42:256–268.
[21] Cordella L, Foggia P, Sansone C, Vento M. An improved algorithm for matching
large graphs. In: Proc. of the 3rd IAPR TC-15 Workshop on Graph-based Repre-
sentations in Pattern Recognition. pp. 149–159.
[22] Foggia P. The VFLib Graph Matching Library, version 2.0.
http://amalfi.dis.unina.it/graph/db/vflib-2.0/doc/vflib.html
[23] Budin N, Majeux N, Caflisch A. Fragment-based flexible ligand docking by evo-
lutionary optimization. Biol Chem 2001; 382:1365–1372.
[24] Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. Structural
basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphospho-
rylated juxtamembrane region. Cell 2001; 106:745–757.
[25] Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity
of progressive multiple sequence alignment through sequence weighting, position-
specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673–
4680.
[26] ˇSali A, Blundell TL. Comparative protein modelling by satisfaction of spatial re-
straints. J Mol Biol 1993; 234:779–815.
Kolb et al., ALTA: Anchor-based library tailoring 16
[27] Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, ˇSali A. Comparative
protein structure modeling of genes and genomes. Annu Rev Biophys Biomol
Struct 2000; 29:291–325.
[28] Altschul SF, Madden TL, Scha¨ffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ.
Gapped BLAST and PSI-BLAST: a new generation of protein database search pro-
grams. Nucleic Acids Res 1997; 25:3389–3402.
[29] Holm L, Sander C. Protein structure comparison by alignment of distance matrices.
J Mol Biol 1993; 233:123–138.
[30] Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M.
CHARMM: A program for macromolecular energy, minimization, and dynamics
calculations. J Comp Chem 1983; 4:187–217.
[31] Momany FA, Rone R. Validation of the general purpose QUANTA 3.2/CHARMm
force field. J Comput Chem 1992; 13:888–900.
[32] No K, Grant J, Scheraga H. Determination of net atomic charges using a modified
partial equalization of orbital electronegativity method. 1. Application to neutral
molecules as models for polypeptides. J Phys Chem 1990; 94:4732–4739.
[33] No K, Grant J, Jhon M, Scheraga H. Determination of net atomic charges using
a modified partial equalization of orbital electronegativity method. 2. Application
to ionic and aromatic molecules as models for polypeptides. J Phys Chem 1990;
94:4740–4746.
[34] Laskowski RA, MacArthur MW, Moss D, Thornton JM. PROCHECK: a pro-
gram to check the stereochemical quality of protein structures. J Appl Cryst 1993;
26:283–291.
[35] Huang D, Caflisch A. Efficient evaluation of binding free energy. J Med Chem
2004; 47:5791–5797.
Kolb et al., ALTA: Anchor-based library tailoring 17
[36] Kolb P, Huang D, Dey F, Caflisch A. Discovery of kinase inhibitors by high-
throughput docking and scoring based on a transferable linear interaction energy
model. J Med Chem 2008; in press.
[37] Aparna V, Rambabu G, Panigrahi SK, Sarma JARP, Desiraju GR. Virtual screening
of 4-anilinoquinazoline analogues as EGFR kinase inhibitors: Importance of hy-
drogen bonds in the evaluation of poses and scoring functions. J Chem Inf Model
2005; 45:725–738.
[38] Sturz A, Bader B, Thierauch KH, Glienke J. EphB4 signaling is capable of medi-
ating ephrinb2-induced inhibition of cell migration. Biochem Biophys Res Comm
2004; 313:80–88.
[39] Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead
selection. Drug Discov Today 2004; 9:430–431.
[40] Mathis G. Probing molecular interactions with homogeneous techniques based on
rare earth cryptates and fluorescence energy transfer. Clin Chem 2003; 41:1391–
1397.
[41] Shoichet BK. Screening in a spirit haunted world. Drug Discov Today 2006;
11:607–615.
[42] Baici A. The specific velocity plot - a graphical method for determining inhibition
parameters for both linear and hyperbolic enzyme-inhibitors. Eur J Biochem 1981;
119:9–14.
[43] Babaoglu K, Shoichet BK. Deconstructing fragment-based inhibitor discovery. Nat
Chem Biol 2006; 2:720–723.
Kolb et al., ALTA: Anchor-based library tailoring 18
Figure legends
Figure 1: Graphical representation of the workflow of the ALTA procedure (top) and
its application to EphB4 (bottom). The first step is the automatic decomposition18 of a
library of compounds (orange rectangle) to obtain the pool of fragments. Afterwards,
fragments selected based on the binding site features are docked10 and ranked accord-
ing to their binding energy.20 Poses for molecules that contain at least one of the top-
ranking fragments are then generated by flexible-ligand docking.23 aNumber of frag-
ments/compounds processed in the individual steps. Docking (steps 3 and 6) was car-
ried out in parallel on two structures of EphB4 differing only in the orientation of the
hydroxyl group of Thr693 in the ATP-binding site. The value of Nmol is the number
of unique fragments (in steps 3-5) or unique molecules (in step 6) originating from the
docking into the two structures. In contrast, Ncommon is the number of fragments or
molecules that were docked to both structures. As an example, there are 1205 unique
anchor fragments, 795 of which have favorable binding energy in both EphB4 structures,
upon merging the two sets of 1000 fragments (one set for each Thr693 orientation) with
most favorable binding energy calculated by SEED. bMost interesting set (mis): flexible-
ligand docking using the three fragments with the highest chemical richness18 as anchors.
cMaximum diversity set (mds): flexible-ligand docking using the three fragments which
are most dissimilar to each other as anchors. The compounds docked using the mds are
a subset of the compounds docked using the mis.
Figure 2: Plot of the response [arbitrary units] versus the concentration of compound 2
on a logarithmic scale. Data obtained with the Omnia Tyr Recombinant Kit KNZ4051
(Biosource, USA) without (a) and with (b) the addition of detergent (0.01% of Triton
X-100). Values in panel (b) were measured in duplicates. The concentration of ATP in
both assays was 125µM, which is close to its Km.
Figure 3: Specific velocity plot42 for compound 2. v0/vi is the ratio of the initial velocities
for the non-inhibited and inhibited reactions at a given ATP concentration. All values
were measured in duplicates, but some of the pairs of data points (especially the blue
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ones) almost completely overlap on the plot. σ is the ratio of the ATP concentration and
its Km, which was 158µM in this experiment. ATP concentrations ranged from 31.25
to 500µM. Intersecting of all curves close to (1,1) indicates that compound 2 is ATP-
competitive. Measurements were carried out by the Omnia kinetic assay as described.
Figure 4: Predicted binding mode of compound 2 (carbon atoms in green) and its anchor
fragment (carbon atoms in light blue) in a homology model of EphB4 (gold surface). The
hydrogen bonds with the hinge region are shown in light blue dashes. Note the signif-
icant overlap in the binding mode of compound and fragment. Figure prepared with
PyMOL (DeLano Scientific, USA).
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Table legends
Table I: Experimental validation of EphB4 inhibitors identified by ALTA. The fragments
used to retrieve the molecules are emphasized in blue. aZ’Lyte FRET-based enzymatic
assay. Compounds 2 and 3 were tested twice. bCerep FRET-based enzymatic assay. (All
assays are described in the Suppl. Mat.) cOmnia kinetic assay. dFree energy of binding
calculated by LIECE (see Methods). ePercent inhibition at specified concentration.
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1
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2D−based
filtering
Flexible ligand docking
Pool of compounds
Fragment docking
Pool of fragments
Decomposition
Subset of compounds
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Screening with
fragments
Fragment ranking
Candidate fragments
Compound ranking
Application of the anchor-based library tailoring approach to the EphB4 kinase.
Step Outcome Nmola Ncommona
original libraries 728202
1 fragments obtained by decomposition 35513
2 fragments remaining after 2D-based filtering 13533
3 fragments forming two hydrogen bonds with hinge 5235 3880
4 anchor fragments selected upon energy ranking 1205 795
5/6 molecules docked using the “mis”b 21418 7034
5/6 molecules docked using the “mds”c 8849 2544
6 molecules forming one or two hydrogen bonds with hinge 9960 3055
Figure 1:
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Table I. EphB4 inhibitors.
enzymatic assays cell-based assay
compound structure MW IC50a IC50b IC50c CHO Ref. [38] predicted ∆Gd
[Da] [µM] [µM] [µM] %e [kcal·mol−1]
1
H2N
N
N
O
O
O S
H
H
349 76 n.d. n.d. n.d. −8.8
2-8
O
O
N N
N
N
R
HN
R=
2 –(CH2)4OH 353 1.4, 1.8 6.8 5.6, 7.9 neg. −11.0
3 –(CH2)3CH3 337 1.5, 1.5 8.3 n.d. neg. −10.7
4 –(CH2)2CH3 323 1.9 n.d. n.d. neg.
5 ortho-methoxy-phenyl 387 27 n.d. n.d. 14% @ 20µM
6 –(CH2)3OCH3 353 50 n.d. n.d. 28% @ 20µM
7 –(CH2)2Ph 385 30% @ 14µMe n.d. n.d. 34% @ 20µM
8 –(CH2)2-meta-methylphenyl 399 29% @ 5µMe n.d. n.d. 14% @ 20µM
Table I:
